Letter From the Editor
Letter From the Editor: Addressing the Racial Gap in Health Care
Feature Article
Artificial Intelligence in Prostate Cancer Diagnosis and Management: State-of-the-Art Approaches and Emerging Innovations
Abstract: Artificial intelligence (AI) is rapidly changing the field of medicine, and prostate cancer is no exception. The significant heterogeneity that characterizes the natural history of […]
In This Issue
From Recent Issues
Feature Article
Artificial Intelligence in Prostate Cancer Diagnosis and Management: State-of-the-Art Approaches and Emerging Innovations
Abstract: Artificial intelligence (AI) is rapidly changing the field of medicine, and prostate cancer is no exception. The significant heterogeneity that characterizes the natural history of […]
Feature Article
Clinical Applications of PARP Inhibitors in Breast, Ovarian, and Prostate Cancer: Current Insights and Future Directions
Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)–deficient cancers, especially those with BRCA1/2 mutations. Since […]
Feature Article
Hemophagocytic Lymphohistiocytosis: New Grading Classification and Targeted Therapies
Abstract: Hemophagocytic lymphohistiocytosis (HLH), both primary/familial HLH and secondary HLH, is associated with multiorgan dysfunction caused by excessive immune activation and cytokine release. The high morbidity […]
Supplements
Case Study Series
PNH Management: A Clinical Case of Ravulizumab–Danicopan Combination Therapy
About the Patient Patient EW is a 56-year-old woman who was diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) 9 years ago, at the age of 47. At […]
Molecular Residual Disease (MRD) Testing: Advancing Clinical Decision-Making in Breast Cancer
Abstract: Circulating tumor DNA (ctDNA) is emerging as a clinically meaningful biomarker across multiple solid tumors, including breast cancer. Advances in personalized, tumor-informed whole-genome sequencing have enabled […]
Clinical Response With Cabozantinib Plus Nivolumab, a First-Line Therapy in Advanced Renal Cell Carcinoma: A Clinical Case Report
In the Clinic . . . SH is a 47-year-old woman with a history of hypothyroidism and menopause who was diagnosed in March 2019 with Fuhrman […]